Searching after extensive treatment
South African MedicalBrief, drawing on News24 reporting, described Chalupsky’s aggressive myeloma and earlier radiation, chemotherapy and stem cell transplantation. A German assessment had not opened the BCMA CAR-T route he had explored.
What Shanghai offered at that stage
The December 2025 report placed him at Ruijin Hospital for tests to determine eligibility for a different, GPRC5D-targeted CAR-T approach. It also covered a separate insurance dispute over earlier medication. It did not confirm that he received the proposed CAR-T treatment or achieved remission.
China Care perspective
What this case helps us understand
Ruijin’s role in this report was to investigate whether a further targeted approach might fit a heavily treated patient. That specialist assessment is itself part of medical capability: it helps define which options remain realistic. The story captures the search and evaluation stage. Preserving that stage in the account gives a fuller picture of cross-border medicine than a collection limited to successful treatment outcomes.
Sources & further reading
Original reporting belongs to the publishers below. This article is an independently written account based on those sources, with editorial interpretation identified above.
- MedicalBrief, citing News24Discovery digs in its heels over cancer treatment for canoe champ (opens in a new tab)
Specialist evaluation and prior treatment; no CAR-T outcome established
China Care did not provide the care described. This story does not imply a relationship with the patient or hospital, or that China Care can arrange the same treatment. Individual outcomes do not predict other patients’ results. This is editorial information, not medical advice.
Published by China Care on 29 October 2026. Patient experiences and treatment access reflect the dates of the cited reporting.